Orion Oyj expanded biosimilar distribution agreement with CuraTeQ Biologics Private Limited in Europe. The original marketing and distribution agreement signed in 2020 covered the Nordics, Austria, Hungary and Slovenia. Under the agreement, Orion will have the right to sell and market CuraTeQ's biosimilars in the Nordics, the Baltics, Austria, Hungary and Slovenia.

All the products under the agreement are still in development or regulatory phases and the launches in Orion territories are estimated to take place in 2023–2026 depending on the success of the development and regulatory approvals.